tiprankstipranks
Basilea Pharmaceutica (CH:BSLN)
:BSLN
Switzerland Market
BSLN
Basilea Pharmaceutica
RESEARCH TOOLSreports
Want to see CH:BSLN full AI Analyst Report?

Basilea Pharmaceutica (BSLN) Ratios

8 Followers

Basilea Pharmaceutica Ratios

CH:BSLN's free cash flow for Q2 2026 was CHF0.87. For the 2026 fiscal year, CH:BSLN's free cash flow was decreased by CHF and operating cash flow was CHF0.27. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
 6.60 5.11 4.85 3.20 2.34
Quick Ratio
 5.97 4.68 4.16 2.64 2.02
Cash Ratio
 4.24 0.60 2.65 1.26 0.49
Solvency Ratio
 0.42 0.29 0.45 0.07 0.06
Operating Cash Flow Ratio
 1.40 1.26 1.63 0.30 0.09
Short-Term Operating Cash Flow Coverage
 28.13 0.00 36.06 0.92 0.19
Net Current Asset Value
CHF 138.12MCHF 97.67MCHF 44.15MCHF -31.15MCHF -66.20M
Leverage Ratios
Debt-to-Assets Ratio
 0.28 0.32 0.43 0.74 0.85
Debt-to-Equity Ratio
 0.51 0.70 1.38 -12.86 -9.03
Debt-to-Capital Ratio
 0.34 0.41 0.58 1.08 1.12
Long-Term Debt-to-Capital Ratio
 0.30 0.37 0.54 1.12 1.19
Financial Leverage Ratio
 1.84 2.20 3.18 -17.32 -10.66
Debt Service Coverage Ratio
 11.70 14.79 12.56 0.87 0.55
Interest Coverage Ratio
 20.82 15.37 14.08 1.71 1.88
Debt to Market Cap
 0.09 0.11 0.20 0.26 0.31
Interest Debt Per Share
 6.98 7.58 9.60 11.66 16.61
Net Debt to EBITDA
 -1.45 1.08 -0.14 2.96 5.74
Profitability Margins
Gross Profit Margin
87.67%83.09%81.45%83.00%81.86%
EBIT Margin
23.90%22.20%29.59%13.74%15.64%
EBITDA Margin
25.72%23.78%30.27%14.71%17.74%
Operating Profit Margin
23.90%22.20%29.34%12.18%12.55%
Pretax Profit Margin
23.72%19.75%28.90%6.64%8.19%
Net Profit Margin
21.15%17.30%37.21%6.63%8.22%
Continuous Operations Profit Margin
21.19%17.34%37.21%6.63%8.22%
Net Income Per EBT
89.17%87.58%128.76%99.90%100.37%
EBT Per EBIT
99.24%88.95%98.50%54.47%65.26%
Return on Assets (ROA)
17.56%14.26%30.10%6.03%5.50%
Return on Equity (ROE)
36.06%31.42%95.80%-104.48%-58.64%
Return on Capital Employed (ROCE)
23.06%22.17%28.83%15.28%12.70%
Return on Invested Capital (ROIC)
20.44%19.29%28.28%13.40%10.00%
Return on Tangible Assets
17.58%14.27%30.15%6.05%5.51%
Earnings Yield
6.40%6.01%15.52%2.47%2.24%
Efficiency Ratios
Receivables Turnover
 3.63 3.67 3.69 5.65 2.39
Payables Turnover
 2.18 2.61 3.37 4.58 140.33
Inventory Turnover
 1.17 1.82 1.22 1.01 1.11
Fixed Asset Turnover
 14.74 12.80 10.98 7.67 6.85
Asset Turnover
 0.83 0.82 0.81 0.91 0.67
Working Capital Turnover Ratio
 1.14 1.23 1.49 1.54 1.77
Cash Conversion Cycle
 244.91 159.76 288.90 344.70 479.97
Days of Sales Outstanding
 100.56 99.39 99.02 64.58 152.42
Days of Inventory Outstanding
 311.61 200.22 298.27 359.77 330.15
Days of Payables Outstanding
 167.26 139.85 108.39 79.65 2.60
Operating Cycle
 412.17 299.61 397.29 424.35 482.57
Cash Flow Ratios
Operating Cash Flow Per Share
 4.69 5.08 6.15 1.19 0.59
Free Cash Flow Per Share
 4.47 4.85 6.01 1.10 0.32
CapEx Per Share
 0.22 0.23 0.14 0.09 0.28
Free Cash Flow to Operating Cash Flow
 0.95 0.95 0.98 0.93 0.53
Dividend Paid and CapEx Coverage Ratio
 21.42 21.69 43.49 13.78 2.14
Capital Expenditure Coverage Ratio
 21.42 21.69 43.49 13.78 2.14
Operating Cash Flow Coverage Ratio
 0.70 0.70 0.67 0.11 0.04
Operating Cash Flow to Sales Ratio
 0.23 0.27 0.36 0.09 0.05
Free Cash Flow Yield
6.76%8.86%14.53%3.12%0.69%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 15.52 16.63 6.44 40.50 44.72
Price-to-Sales (P/S) Ratio
 3.31 2.88 2.40 2.69 3.68
Price-to-Book (P/B) Ratio
 5.04 5.22 6.17 -42.32 -26.22
Price-to-Free Cash Flow (P/FCF) Ratio
 14.79 11.28 6.88 32.04 144.75
Price-to-Operating Cash Flow Ratio
 14.10 10.76 6.72 29.72 76.99
Price-to-Earnings Growth (PEG) Ratio
 -1.28 -0.34 0.01 -2.75 -0.16
Price-to-Fair Value
 5.04 5.22 6.17 -42.32 -26.22
Enterprise Value Multiple
 11.40 13.17 7.78 21.22 26.47
Enterprise Value
 725.56M 727.96M 490.88M 492.00M 693.80M
EV to EBITDA
 11.40 13.17 7.78 21.22 26.47
EV to Sales
 2.93 3.13 2.35 3.12 4.70
EV to Free Cash Flow
 13.12 12.29 6.76 37.24 184.87
EV to Operating Cash Flow
 12.51 11.72 6.60 34.54 98.33
Tangible Book Value Per Share
 13.11 10.44 6.67 -0.88 -1.80
Shareholders’ Equity Per Share
 13.12 10.47 6.70 -0.83 -1.75
Tax and Other Ratios
Effective Tax Rate
 0.11 0.12 -0.29 <0.01 >-0.01
Revenue Per Share
 20.00 19.02 17.25 13.15 12.46
Net Income Per Share
 4.23 3.29 6.42 0.87 1.02
Tax Burden
 0.89 0.88 1.29 1.00 1.00
Interest Burden
 0.99 0.89 0.98 0.48 0.52
Research & Development to Revenue
 0.49 0.46 0.37 0.49 0.50
SG&A to Revenue
 0.15 0.15 0.15 0.21 0.21
Stock-Based Compensation to Revenue
 0.00 0.02 0.02 0.03 0.02
Income Quality
 1.11 1.54 0.96 1.36 0.58
Currency in CHF